A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme

Neuro-Oncology

Volumn 14, Issue 9, 2012, Pages 1178-1184

  Rønning, Pål A ^a   Helseth, Eirik ^a   Meling, Torstein R ^a   Johannesen, Tom B ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

Glioblastoma; Glioma; Population based; Treatment outcome

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; DRUG EFFICACY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION RESEARCH; POSTOPERATIVE PERIOD; PRESCRIPTION; RADIATION DOSE FRACTIONATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NORWAY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; REGISTRIES; SURVIVAL RATE;

EID: 84867541653     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos153     Document Type: Article

References (27)

1. Paszat L, Laperriere N, Groome P, Schulze K, Mackillop W, Holowaty E. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51(1):100-107.
2. Helseth R, Helseth E, Johannesen TB, et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand. 2010;122(3):159-167.
3. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guidedsurgerywith 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncology. 2006;7(5):392-401.
4. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. New Engl J Med. 1980;303(23):1323-1329.
5. Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981;47(4):649-652.
6. Fine HA, Dear K B G, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation-therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71(8):2585-2597.
7. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
8. Shahar T, Nossek E, Blumenthal DT, et al. Trial to survive: the impact of enrollment in clinical trials on survival of patients with Glioblastoma. Neurosurgery. 2009;65(2):425-425.
9. The Cancer Registry of Norway. The Cancer Registry of Norway, Institute of Population-based Cancer Research. http://www.kreftregisteret.no/en/. Accessed June 10, 2010.
10. Folkehelseinstituttet. http://www.norpd.no/. Accessed June 10, 2010.
11. Helseth A, Langmark F, Mork SJ. Neoplasms of the central nervous system in Norway. I. Quality control of the registration in the Norwegian Cancer Registry. Apmis. 1988;96(11):1002-1008.
12. Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218-1231.
13. Stefano Iacus GK, Giuseppe Porro CEM: Software for Coarsened Exact Matching. 2009; http://CRAN. R-project.org/package=cem.
14. Rbounds: Perform Rosenbaum bounds sensitivity tests for matched data. [computer program]. Version R package version 0.7 2011.
15. Rosenbaum PR. Observational Studies, 2nd ed. New York: Springer; 2002.
16. Stare J, Harrell FE, Heinzl H. BJ: an S-Plus program to fit linear regression models to censored data using the Buckley-James method. Comput Meth Prog Bio. 2001;64(1):45-52.
17. R: A Language and Environment for Statistical Computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2010.
18. Scoccianti S, Magrini SM, Ricardi U, et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery. 2010;67(2):446-458.
19. Rogne SG, Konglund A, Meling TR, et al. Intracranial tumor surgery in patients.70 years of age: is clinical practice worthwhile or futile? Acta Neurol Scand. 2009;120(5):288-294.
20. Barnholtz-Sloan JS, Williams VL, Maldonado JL, et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. Journal of Neurosurgery. 2008;108(4):642-648.
21. Mangiola A, Maira G, De Bonis P, et al. Glioblastoma multiforme in the elderly: A therapeutic challenge. J Neuro-Oncol. 2006;76(2):159-163.
22. Brandes AA, Compostella A, Blatt V, Tosoni A. Glioblastoma in the elderly: current and future trends. Crit Rev Oncol Hematol. 2006;60(3):256-266.
23. Chamberlain MC, Chalmers L. A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol. 2007;82(2):207-209.
24. Ewelt C, Goeppert M, Rapp M, Steiger HJ, Stummer W, Sabel M. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. J Neuro-Oncol. 2011;103(3):611-618.
25. Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007;15(3):199-236.
26. Gorlia T, Van Den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9(1):29-38.
27. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.